Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma gets...

    Aurobindo Pharma gets USFDA approval for blood pressure drug

    Written by savita thakur thakur Published On 2016-04-27T11:48:16+05:30  |  Updated On 27 April 2016 11:48 AM IST
    Aurobindo Pharma gets USFDA approval for blood pressure drug

    New Delhi : Aurobindo Pharma said it has received final approval from the US health regulator to manufacture and market generic version of blood pressure treatment drugs Amlodipine and Valsartan tablets.


    The approval by the US Food and Drug Administration (USFDA) is for multiple strengths of 5mg/160mg, 5mg/320mg and 10mg/320 mg, the company said in a BSE filing.


    This product is expected to be launched in the first quarter of 2016-17, it added.


    The drug is bio-equivalent and therapeutically equivalent to the reference listed product Exforge of Novartis Pharmaceuticals Corporation, it said.


    Citing IMS data, the company said the approved product had an estimated market size of USD 123 million in the 12 month period ended February 2016.


    This is the 71st ANDA to be approved out of Unit VII of the company's formulation facility for oral non-antibiotic products in Hyderabad, Aurobindo Pharma said.


    Shares of the company were trading 0.44 per cent up at Rs 768.60 apiece on the BSE.

    AmlodipineANDAAurobindo PharmaBlood Pressure DrugIMSNovartisUS Food & Drug AdministrationUSFDAValsartan
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok